^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Excerpt:
Response to EGFR TKIs of NSCLCs harboring EGFR exon 20 insertion mutations.
DOI:
10.1126/scitranslmed.3007205
Evidence Level:
Resistant: D – Preclinical
Title:

Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation

Published date:
06/11/2020
Excerpt:
In this study, we generated a Ba/F3 cell line expressing EGFR H773_V774 insH mutation and identified a synergistic treatment (EA with erlotinib) that markedly inhibited the viability of Ba/F3-insH cells in vitro and in vivo.
DOI:
10.1111/1759-7714.13487